Welcome Back

By becoming a RECADEMY member, you agree to site’s user

Buprenorphine Availability At Pharmacies Increased In Both Rural & Urban Counties

A larger share of U.S. retail pharmacies consistently dispensed buprenorphine between 2019 and 2025, with the increase greater in rural counties than urban counties. The percentage of rural pharmacies dispensing buprenorphine for opioid use disorder (OUD) increased from 64.9% in 2019 to 80.0% in 2025, compared with an increase from 64.8% to 72.4% among urban pharmacies.

Despite the greater increase in rural pharmacy dispensing, buprenorphine administration in emergency departments (EDs) remained less common in rural counties than urban counties. The percentage of urban EDs administering buprenorphine increased from 6.7% in 2019 to 31.4% in 2025, compared with an increase from 2.3% to 10.3% among rural EDs.

Buprenorphine administration also became more common during ED visits for OUD or non-fatal opioid overdose, rising from 33.9 to 111.1 per 1,000 visits in urban counties and from 25.2 to 103.3 per 1,000 visits in rural counties.

The number of buprenorphine prescribers also increased between 2019 and 2025, rising from 0.1 to 0.4 per 1,000 people in urban counties and from 0.1 to 0.2 in rural counties. At the same time, the number of individuals per prescriber decreased from 48.7 to 25.7 in urban counties and from 60.1 to 36.3 in rural counties. Prescriptions per prescriber also decreased, from 312.8 to 116.0 in urban counties and from 469.2 to 195.8 in rural counties.

Despite growth in the number of prescribers, buprenorphine prescribing became increasingly concentrated among high-volume prescribers. The top 10% of prescribers accounted for 84.8% of retail pharmacy buprenorphine prescriptions in urban counties in 2025, up from 71.1% in 2019. In rural counties, their share increased from 65.6% to 81.0%.

Across the study period, buprenorphine treatment initiation and 180-day retention rates were higher in rural counties than urban counties. Rural initiation was 14.2 per 100,000 people compared with 11.8 per 100,000 in urban counties, while 180-day treatment retention was 23.1% in rural counties compared with 17.7% in urban counties.

The findings were based on an analysis of data from 2019 through 2025 using two national data sources. Researchers used IQVIA data to assess buprenorphine dispensing by retail pharmacies and the Premier Healthcare Database to examine ED administration. IQVIA includes approximately 94% of U.S. retail pharmacy prescriptions. A pharmacy was considered to have buprenorphine available if it dispensed at least one buprenorphine prescription in each month it operated during a given year.

The Premier Healthcare Database is an all-payer database containing information from approximately 1,400 hospitals. The database includes an average of approximately 8 million inpatient admissions and 86 million outpatient visits annually.

The findings were reported in Buprenorphine Dispensed By Pharmacies & Administered In Emergency Departments In Urban & Rural Areas—United States, 2019–2025 by Gery P. Guy Jr., Ph.D.; Yijie Chen, Ph.D.; Kun Zhang, Ph.D.; and colleagues.

The researchers concluded that rural communities relied more heavily on pharmacies for buprenorphine access than urban communities. To improve access to OUD treatment and reduce overdose risk, they recommended improving pharmacy availability, supporting ED-based treatment, and sustaining federal telehealth flexibilities.

For more information, contact: U.S. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, Georgia 30329; 800-232-4636; Email: CDCInfo@cdc.gov; Website: https://www.cdc.gov/

Want To Read More?

This content is exclusive to RECADEMY members.

RECADEMY is a comprehensive, research-based, online learning collaborative designed to provide critical information about emerging substance use disorder treatment topics and models of care.

Sign in or join the RECADEMY community for free today.